Table 3 Incidence of adverse reactions induced by the two chemotherapeutic regimens (n%)
Adverse reactions | Nab-TC (n = 40) (n)% | TC (n = 40) (n%) | P value | P value | ||
|---|---|---|---|---|---|---|
I–IV | III–IV | I–IV | III–IV | I–IV | III–IV | |
Neutropenia | 26 (65.0) | 12 (30.0) | 29 (72.5) | 16 (40.0) | 0.469 | 0.348 |
Anemia | 15 (37.5) | 2 (5.0) | 16 (40.0) | 5 (12.5) | 0.818 | 0.235 |
Thrombocytopenia | 7 (17.5) | 3 (7.5) | 6 (15.0) | 1 (2.5) | 0.762 | 0.305 |
Peripheral neuropathy | 30 (75.0) | 18 (45.0) | 22 (55.0) | 7 (17.5) | 0.061 | 0.008 |
Nausea and vomiting | 16 (40.0) | 4 (10.0) | 35 (87.5) | 15 (37.5) | 0.000 | 0.004 |
Liver dysfunction | 4 (10.0) | – | 7 (17.5) | – | 0.330 | – |
Kidney dysfunction | 2 (5.0) | – | 3 (7.5) | – | 0.644 | – |
Allergic reaction | 1 (2.5) | – | 1 (2.5) | – | 1.0 | – |
Arrhythmia | 4 (10.0) | – | 7 (17.5) | – | 0.330 | – |
High blood sugar | 2 (5.0) | – | 8 (20.0) | – | 0.043 | – |
Hair loss | 40 (100) | – | 40 (100) | – | 1.0 | - |